Illinois Municipal Retirement Fund Buys 7,483 Shares of Glaukos Corporation (NYSE:GKOS)

Illinois Municipal Retirement Fund increased its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 25.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,901 shares of the medical instruments supplier's stock after buying an additional 7,483 shares during the quarter. Illinois Municipal Retirement Fund owned 0.07% of Glaukos worth $3,632,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. William Blair Investment Management LLC acquired a new position in shares of Glaukos during the 4th quarter worth about $121,390,000. Alliancebernstein L.P. raised its holdings in Glaukos by 1,235.4% during the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock worth $122,374,000 after acquiring an additional 755,035 shares in the last quarter. Norges Bank acquired a new position in Glaukos during the fourth quarter valued at approximately $84,490,000. Gilder Gagnon Howe & Co. LLC boosted its position in Glaukos by 25.3% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock valued at $123,742,000 after purchasing an additional 166,677 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in Glaukos by 266.2% in the fourth quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier's stock valued at $30,093,000 after purchasing an additional 145,890 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Performance

NYSE:GKOS traded down $0.68 during mid-day trading on Tuesday, hitting $102.61. 167,530 shares of the stock were exchanged, compared to its average volume of 736,262. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.62 and a current ratio of 6.49. The firm's 50-day simple moving average is $95.06 and its 200 day simple moving average is $116.71. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The stock has a market capitalization of $5.86 billion, a price-to-earnings ratio of -43.30 and a beta of 0.80.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 31.40% and a negative return on equity of 10.66%. The company had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the previous year, the business posted ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% on a year-over-year basis. As a group, equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Morgan Stanley dropped their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Piper Sandler dropped their price target on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Stifel Nicolaus decreased their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Needham & Company LLC lowered their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Stephens cut their target price on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.